The company plans to submit IND applications for LTX-002 and LTX-001 by the end of 2024 and commence first-in-human clinical trials in early 2025.
Founders
Asa Abeliovich
Company Description
Leal Therapeutics is a biotechnology company dedicated to developing novel precision medicines for patients with high-need central nervous system disorders. The company focuses on antisense oligonucleotide (ASO) and small molecule therapeutics.